



THE POWER OF PRECISION.
FOR EVERY CANCER PATIENT.
TODAY

ØU LS Investor Konferencer - 22nd January 2023 - Fernando Andreu, CEO




DISCLAIMER – FORWARD LOOKING STATEMENTS

Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and might include, but is not limited to, the expected development of the Company’s business, projects, and execution of the Company’s vision and growth strategy; completion of the Company’s projects that are currently underway, in development or otherwise under consideration; renewal of the Company’s current customer, supplier and other material agreements; and future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.


These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

CURRENT CRC TREATMENT: TRIAL-AND-ERROR



What if we could tell in advance which patients will respond to which therapy?




Improve patient outcomes



Avoid unnecessary toxicity

Avoid unnecessary costs

WE CAN, WITH FUNCTIONAL DRUG SENSITIVITY TESTING





IndiTreat®: **INDIVIDUAL TREATMENT** selection based on tumor sensitivity profile



PATIENT A - SENSITIVITY RESULT


DRUG TESTED	Low	Medium	High
Drug A		◆	
Drug B		◆	
Drug C	◆		
Drug D			◆
Drug E		◆	

THERAPY DECISION MAKING IN CRC - THE MARKET




- In **Stage IV**, 1.3M patients start treatment every year.
- Domain of IndiTreat Start, Extend and Explore.
- **Theoretical** market for this group alone would be in the range of **2.1Bn USD per year** at distributor price.
- **Additional opportunities** for future IndiTreat tests to guide treatment in **Stages II and III**.

f-DST TECHNOLOGY ADOPTION CURVE (mCRC only)



Addressable market size (M EUR)



Adoption rate as % of theoretical market

FROM 'THEORETICAL' TO 'ADDRESSABLE'

f-DST TECHNOLOGY ADOPTION CURVE (mCRC only)



“Although gene-based companion diagnostics are becoming increasingly common, there is a complex relationship between genotype and phenotype, and relying on genomic data alone risks missing vital information”

“In terms of barriers, the number one thing that stands out is the level of rigidity and inertia that you see in diagnostic pathways”


“Europe is a complicated market. It is still a patchwork of countries and regulations”

“Having a shared regulatory process doesn't mean you get paid: you have to go into every country with its own policy, reimbursement process etc.”




VOICE OF CUSTOMER


Q27: New tools to support therapy decision-making in CRC are urgently needed



Q7: How satisfied are you with the outcome of the 1st line therapies you select




Q13: How satisfied are you with the outcome of the 3rd line therapies you select



VOICE OF CUSTOMER

Q15: Drug Sensitivity Testing can be a useful tool to help select the right treatment for an individual patient




“It provides a guidance for drugs that do not have an associated biomarker” [83%]


“Genomics-only cannot predict the response profile of a patient” [55%]

VOICE OF CUSTOMER


Q23: I would like to test a Drug Sensitivity Test with my patients



Q24: I am likely to use this kind of tests in the coming 12 months



COMPETITIVE LANDSCAPE: INCREASING PRESSURE



- Several companies developing IVD products and clinical studies ongoing
- Increased funding activity (e.g.: Xilis 89M USD between 2021 and 2022)
- Globalization (e.g.: Invitrocue presence in Europe, OncoPrecision move to US, SEngine activities in Europe...)
- M&A activity
 - 2019 Helomics - Precision Therapeutics
 - 2021 Exscientia - Allcyte / CrownBio - Ocello
 - 2022 Molecular Devices - Cellesce / CliniSciences - Oncomedics
- We expect to see more moves as companies build their positions (still in pre-revenue space)




2cureX COMPETITIVE ADVANTAGES

- Proven and IP protected technology that provides better fidelity to the original tumor and uses AI powered image analysis
- 3 CE-marked IVD tests (IndiTreat® Start, Extend and Explore) supporting mCRC therapy decisions.
- ISO 13485 certification.
- Solid clinical evidence of patient benefit.
- Commercial and logistics reach in 20 countries.
- 24 hospitals enrolled in the early access program (IGNITE).
- Ongoing conversations with more than 100 additional hospitals.
- An expert and experienced team.




Control Group



■ SD ■ PD

IndiTreat® Group



■ SD ■ PD


2022 GOALS REVIEW

		End '21	Goal	End '22
	Countries with IndiTreat® presence	11	20	20
	Hospitals enrolled in IGNITE program	1	30*	24
	Products in portfolio (mCRC) CE-Marked	2	3	3

Despite the complex environment, 2cureX has fulfilled the goals for 2022 except for a slight delay in IGNITE program enrollment and we have expanded the lead to our competitors towards achieving routine clinical use of 3D tumoroids-base tests.

* Goal had been revised in Q4 to 20 hospitals

STRATEGIC PRIORITIES 2cureX 2023



Increase penetration in European Market (short term)

- Joint work with distributors in local activities
- IGNITE program to facilitate experience to early users
- Clinical Trials to support reimbursement and guidelines change
- New countries to cover pending relevant markets



Growing our market share
“below the curve”

Expand the market opportunity (mid term)

- New product (IndiTreat® Neo) to address earlier stage CRC patients
- Prepare geographic expansion beyond Europe (Automation)
- Enable transition from service to product supplier (Automation)

Pushing and expanding the
curve

2023 GOALS

		Goal
	Countries with IndiTreat® presence	25
	Patient samples tested	>500
	Expansion of IndiTreat® portfolio	IndiTreat® Neo Performance Assessment phase completed
	IndiTreat® automation	Prototype ready to be tested at hospital
	IndiTreat® decentralization to hospitals	First IndiTreat® test run directly at a hospital
	Revenue	6M SEK from which at least 3M SEK coming from sales

TO REMEMBER...

- There is a huge unmet clinical need to better use existing cancer drugs.
- Patient outcomes, toxicity and costs need to be balanced through informed decisions.
- Functional Drug Sensitivity Testing based on 3D microtumors addresses the issue.
- Opening a new category of *In Vitro Diagnostics* tests with multi-billion-dollar potential.
- Scalable to additional disease stages and cancer types.
- Increasing maturity of the segment but 2cureX keeps the lead.
- We have delivered on the 2022 goals, significantly de-risking the case.
- Ambitious short and mid term plans, and the team to make them happen, are in place.



Thank You!

Sign up for News at
www.2curex.com

and follow us on:

